X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (873) 873
index medicus (872) 872
antifungal agents - therapeutic use (613) 613
echinocandins (472) 472
lipopeptides (412) 412
male (394) 394
echinocandins - therapeutic use (374) 374
female (357) 357
caspofungin (353) 353
antifungal agents - adverse effects (320) 320
pharmacology & pharmacy (305) 305
middle aged (284) 284
adult (258) 258
infectious diseases (258) 258
antifungal agents - administration & dosage (256) 256
candidiasis - drug therapy (238) 238
micafungin (236) 236
treatment outcome (234) 234
echinocandins - adverse effects (229) 229
voriconazole (222) 222
mycoses - drug therapy (218) 218
liposomal amphotericin-b (206) 206
aged (203) 203
echinocandins - administration & dosage (203) 203
antifungal agents (197) 197
fluconazole (192) 192
microbiology (192) 192
amphotericin-b (189) 189
candidiasis (189) 189
antifungal agents - pharmacology (186) 186
aspergillosis (182) 182
aspergillosis - drug therapy (171) 171
mycoses (170) 170
echinocandin (152) 152
peptides, cyclic - therapeutic use (152) 152
fungal-infections (149) 149
antifungal agents - pharmacokinetics (148) 148
drug therapy, combination (148) 148
adolescent (137) 137
amphotericin b - therapeutic use (136) 136
invasive candidiasis (134) 134
anidulafungin (133) 133
transplantation (133) 133
animals (129) 129
invasive fungal-infections (129) 129
pharmacokinetics (128) 128
amphotericin b (126) 126
drug therapy (126) 126
child (122) 122
health aspects (121) 121
lipopeptides - therapeutic use (121) 121
triazoles - therapeutic use (117) 117
immunology (115) 115
therapy (113) 113
candidemia (106) 106
candida (105) 105
care and treatment (103) 103
mortality (101) 101
mycology (101) 101
epidemiology (100) 100
immunocompromised host (100) 100
fungal infections (97) 97
infections (96) 96
retrospective studies (96) 96
invasive aspergillosis (95) 95
double-blind (93) 93
echinocandins - pharmacokinetics (92) 92
risk factors (92) 92
candida - drug effects (91) 91
echinocandins - pharmacology (90) 90
safety (90) 90
drug resistance, fungal (89) 89
lipopeptides - adverse effects (89) 89
research (87) 87
antifungal therapy (86) 86
microbial sensitivity tests (85) 85
lipopeptides - administration & dosage (84) 84
efficacy (83) 83
in-vitro activity (81) 81
medicine & public health (81) 81
neutropenia (78) 78
pediatrics (78) 78
drug interactions (77) 77
hematology (77) 77
pyrimidines - therapeutic use (77) 77
aged, 80 and over (76) 76
child, preschool (75) 75
fluconazole - therapeutic use (75) 75
internal medicine (75) 75
amphotericin b - administration & dosage (74) 74
mycoses - prevention & control (74) 74
young adult (74) 74
oncology (73) 73
dosage and administration (72) 72
infant (72) 72
peptides, cyclic - adverse effects (70) 70
candidiasis - microbiology (69) 69
infection (69) 69
antifungal (67) 67
analysis (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (942) 942
Spanish (38) 38
Japanese (16) 16
German (12) 12
French (7) 7
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 01/2015, Volume 162, Issue 2, pp. 81 - 89
Journal Article
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 11/2015, Volume 41, Issue 11, pp. 1931 - 1940
Systemic antifungal therapy (SAT) of invasive candidiasis needs to be initiated immediately upon clinical suspicion. Controversies exist about adequate time... 
Causal inference | Pediatrics | Emergency Medicine | Antifungal | Invasive candidiasis | Intensive / Critical Care Medicine | Intensive care unit | Pain Medicine | Pneumology/Respiratory System | Medicine & Public Health | Outcome | De-escalation | Sepsis | Anesthesiology | ADULT PATIENTS | GLABRATA | CANDIDEMIA | INTENSIVE-CARE UNITS | DOUBLY ROBUST ESTIMATION | COLONIZATION | PROSPECTIVE MULTICENTER | THERAPY | SEPTIC SHOCK | BLOOD-STREAM INFECTIONS | CRITICAL CARE MEDICINE | Antifungal Agents - adverse effects | Prospective Studies | Humans | Middle Aged | Fluconazole - administration & dosage | Critical Illness | Fluconazole - adverse effects | Intensive Care Units - statistics & numerical data | Male | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Candidiasis, Invasive - mortality | Echinocandins - administration & dosage | Candidiasis, Invasive - diagnosis | Multicenter Studies as Topic | Candidiasis, Invasive - drug therapy | Female | Severity of Illness Index | France - epidemiology | Time-to-Treatment - statistics & numerical data | Hospital Mortality | Comorbidity | Logistic Models | Disease Progression | Outcome and Process Assessment (Health Care) - statistics & numerical data | Echinocandins - adverse effects | Survival Analysis | Echinocandins - therapeutic use | Observation | Aged | Candidiasis, Invasive - prevention & control | Antifungal Agents - administration & dosage | Complications and side effects | Candidiasis | Care and treatment | Critically ill | Antifungal agents | Research | Health aspects | Risk factors | Index Medicus | Life Sciences
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 04/2015, Volume 60, Issue 7, pp. 997 - 1006
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2004, Volume 351, Issue 14, pp. 1391 - 1402
Journal Article
Clinical Microbiology and Infection, ISSN 1198-743X, 07/2012, Volume 18, Issue 7, pp. 680 - 687
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2014, Volume 58, Issue 9, pp. 1219 - 1226
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2002, Volume 347, Issue 25, pp. 2020 - 2029
Journal Article
Journal Article
Journal Article